INTRODUCTION
============

The tau proteins are vertebrate neuronal microtubule (MT)-associated proteins (MAPs) generated by alternative splicing from a single gene ([@B88]; [@B3]). During neuronal development, tau becomes enriched in the axon, where it remains concentrated in the healthy brain. Neuronal development is also accompanied by a shift in the isoform pattern toward the expression of longer tau isoforms. In Alzheimer's disease (AD) and other tauopathies, tau redistributes from the axon to the somatodendritic compartment, where it aggregates into neurofibrillary tangles (NFTs) in a hyperphosphorylated state. Changes in tau localization and a gain of toxic function are considered to have a central role in the disease process ([@B79]; [@B82]). In addition, dysfunction related to posttranslational modifications leading to MT depolymerization and impaired axonal transport may play a role ([@B6]). Finally, transsynaptic and exosynaptic tau propagation may contribute to the disease process ([@B60]).

MTs are the most dominant binding partners of tau, with the majority of tau being associated with MTs in axons under physiological conditions ([@B84]; [@B55]; [@B96]). Tau's functional organization with respect to its interaction with MTs has been thoroughly analyzed in vitro, in silico, and in nonneuronal cell models but not in the axonal compartment. Bioinformatic and biochemical studies show that the MT-binding domain (MBD) of tau consists of three or four repeat regions (RRs), which bind to MTs via small groups of evolutionarily conserved residues ([@B57]; [@B11]; [@B38]; [@B51]; [@B92]). In addition, regions flanking the MBD could be important because they increase tau's assembly-promoting activity and modulate its binding to MTs in vitro and in nonneuronal cells ([@B9]; [@B39]; [@B58]; [@B78]). However, the extent to which these data can be extrapolated to the axonal environment in living neurons is unknown.

Tau is subject to many posttranslational modifications in health and disease, which are likely to affect its localization and function ([@B40]; [@B95]; [@B66]; [@B67]). Phosphorylation is the best-studied tau modification, and experimental evidence indicates that tau gains toxic properties in response to increased phosphorylation at disease-relevant sites ([@B80]; [@B28]; [@B86]). Many of the physiological and pathological phosphorylation sites are located in regions that flank the MBD and might modulate tau's interaction with MTs and other cellular components ([@B62]; [@B27]; [@B22]; [@B18]; [@B54]; [@B100]). Another disease-relevant posttranslational modification could be proteolytic cleavage of tau, which produces truncated tau fragments. Tau truncation appears to be an early event in AD ([@B81]; [@B31]) and may produce neurotoxic fragments ([@B74]; [@B56]), generate products that show increased release from neurons ([@B53]), or produce fragments with a modified MT interaction ([@B21]). Still, the consequences of posttranslational modifications of tau for its behavior in the axonal compartment remain enigmatic.

The MTs in neuronal processes have a characteristic organization, in that they form a closely packed parallel array and show a uniform plus-end-out orientation in the axon, which specialize them for efficient transport ([@B41]; [@B42]; [@B2]). The neurites of neuronally developed PC12 cells represent a good model because the processes exhibit axon-like MT orientation ([@B70]). We previously showed that the organization of axonal MTs influences the way tau interacts with them and that the behavior of tau in cellular processes is noticeably different from that in vitro ([@B46]). In particular, tau interacts with MTs via a kiss-and-hop mechanism, that is, it rapidly hops between MTs, residing only transiently on each of them ([@B47]). Nevertheless, it still needs to be elucidated how the interaction of tau with MTs in the axon is modulated and whether it is affected under conditions that prevail during disease such as increased phosphorylation or truncation of tau.

Among live-cell fluorescence microscopy techniques, fluorescence recovery after photobleaching (FRAP) and fluorescence decay after photoactivation (FDAP) have been applied to study tau mobility and the tau--MT interaction in living cells ([@B55]; [@B96]; [@B34]; [@B46]). Tau is tagged by a variant of green fluorescent protein (GFP)---for example, enhanced GFP for FRAP and photoactivatable GFP (PAGFP) for FDAP. A defined region within the cell is irreversibly bleached or photoactivated by a focused laser flash, and the fluorescence intensity distribution as a function of time is monitored in the region of interest. The recovery/decay transient is fitted by a mathematical model to yield mobility and binding properties of the target molecule. An advantage of fluorescence photoactivation compared with alternative methods lies in the fact that only photoactivated molecules are visible in the experimental setup. Thus newly synthesized molecules will not be fluorescent, which simplifies analysis of the results of live-cell studies ([@B75]). Furthermore, photoactivation occurs more rapidly and requires lower intensity of irradiation, thereby reducing the risk of phototoxicity compared with classical photobleaching approaches ([@B75]).

We used FDAP to study the functional mapping of tau's domain organization in axon-like processes. Our study reveals considerable differences to previous in vitro data. On one hand, tau isoform variation has only a minor influence on MT binding. On the other hand, MT binding is robustly enhanced by the presence of a conserved C-terminal pseudorepeat region (PRR) in tau's C-terminus in an isoform-independent manner. Disease-associated mutations in the PRR increase the dynamicity of the tau--MT interaction, whereas pseudohyperphosphorylation of tau strongly reduces MT binding. We believe that our results contribute to an understanding of the pathological processes that lead to a redistribution of tau from the axon to the somatodendritic compartment, which is one of the early events in tauopathies.

RESULTS
=======

The presence of tau's PRR greatly enhances MT binding in axon-like processes
----------------------------------------------------------------------------

Human CNS tau isoforms contain an MBD in the C-terminal half of the protein that consists of three or four repeat regions (RR1--RR4; [Figure 1A](#F1){ref-type="fig"}, left). In addition, the C-terminus contains an extra segment, which appears to be a truncated fourth repeat (pseudorepeat region \[PRR\]; [@B13]). To dissect the interaction of tau with MTs in the process of living neuronal cells, we prepared a panel of C-terminal tau deletion constructs containing different numbers of RRs and the PRR. All constructs were fused to PAGFP at its amino terminus to minimize potential interference with the MT interaction. We had previously shown that such a fusion does not interfere with tau's interaction with axonal membrane components, which is mediated by the amino-terminal projection domain and contributes to tau's localization in the neuronal process ([@B96]; [@B34]). The constructs were present as single polypeptides in transfected PC12 cells, indicating their integrity. They separated at a 40--50% higher molecular weight than calculated from their sequence ([Figure 1A](#F1){ref-type="fig"}, right), which is in agreement with earlier studies ([@B62]; [@B96]).

![Tau's PRR greatly enhances MT binding in processes of living neuronal cells. (A) Schematic representation of the tau deletion constructs with N-terminal PAGFP fusion. The MT-binding repeat regions (RR1--RR4) are indicated by the yellow boxes and the PRR by the orange box. Adult-specific exons in the N-terminus are shown in dark gray (N1, N2). Right, immunoblots of cellular lysates after transfection with the respective tau constructs. Detection used anti-GFP antibody. Molecular weight standards are indicated on the far right, and respective molecular weights as determined from the electrophoretic separation are indicated beneath. (B) Schematic representation of the photoactivation approach (left) and representative time-lapse recordings of fluorescence distribution after expression of PAGFP-tau441wt and -tauΔ369 (right). Photoactivation was performed in a neuronally differentiated PC12 cell. A segment of 2*R* in length in the middle of a cellular process of length *L* (*L* \>\> *R*) was photoactivated, and the fluorescence distribution was monitored over time. Dashed white line, outline of the cell; white box, region of activation; red box, region of fluorescence recording. (C) FDAP plots (left) and a diagram of the effective diffusion constants (right) for the different constructs. Values are mean ± SEM (error bars). (D) Bar plots showing *k*\*~on~ and *k*~off~ values of the respective constructs. The numbers are relative to tau441wt. The box represents 50% of the population, whiskers range from 5 to 95%, crosses correspond to the minimal and maximal values, the horizontal line shows the median, and the black square shows the mean value. Statistically significant differences relative to full-length tau (tau441wt) are indicated on top (asterisks) and between neighboring columns by dollar signs. Reference values for full-length tau (tau441wt) were determined from three independent sets of cells, with 9--13 cells/set. For other constructs, 6--23 cells were evaluated. \*^,\$^*p* \< 0.05, \*\*^,\$\$^*p* \< 0.01; \*\*\*^,\$\$\$^*p* \< 0.001.](3537fig1){#F1}

After neuronal differentiation of transfected PC12 cells, PAGFP was activated within a segment in the middle of the process by a laser flash at 405-nm wavelength ([Figure 1B](#F1){ref-type="fig"}), and FDAP was recorded in the activated region as a function of time ([Figure 1C](#F1){ref-type="fig"}, left). The FDAP decay can be used as a measure of protein dynamics in the corresponding cellular compartment. Deletion of tau's extreme C-terminus (tauΔ401) yielded a construct that exhibited a slower decay then wild-type (wt) tau (tau441wt), indicating enhanced binding ability of tauΔ401 (red vs. black curve in [Figure 1C](#F1){ref-type="fig"}, left). In contrast, further deletion resulting in the removal of the PRR (tauΔ369) led to a much faster decay than with tauΔ401 and tau441wt (dark blue vs. red and black curves in [Figure 1C](#F1){ref-type="fig"}, left). Calculation of the effective diffusion constant ([@B96]) yielded *D*~eff~ = 0.22 ± 0.01 μm^2^/s (mean ± SEM, *n* = 26) for full-length tau (tau441wt). Comparing the values for the different constructs confirmed the influence of the PRR and indicated that its deletion increased *D*~eff~ by a factor of ∼17 (*D*~eff~ = 1.41 ± 0.20 and 0.06 ± 0.04 μm^2^/s for tauΔ369 and tauΔ401, respectively; [Figure 1C](#F1){ref-type="fig"}, right). Further deletions moderately increased *D*~eff~. A second major increase of *D*~eff~ was observed for a construct containing only one RR (tauΔ276; [Figure 1C](#F1){ref-type="fig"}, right). This might imply a special role for RR2, which is present only in the adult-specific four-repeat tau isoforms, or might be due to a requirement of at least two repeat regions for efficient binding. A construct similar to tauΔ276 in which RR1 was replaced by the PRR (tauN-PRR) did not exhibit stronger binding than tauΔ276, indicating that the PRR requires the presence of other repeats to exert its function as an amplifier of the MT interaction.

A rigorous treatment of FDAP data requires that the general reaction-diffusion equations describing the underlying protein dynamics be solved ([@B89]). The method introduced by [@B96]) relies on an approximation to the full reaction-diffusion system and does not allow an assessment of both association (*k*~on~) and dissociation (*k*~off~) constants, which directly reflect the on-off dynamics of tau on MTs. Furthermore, using this kind of FDAP data treatment makes it impossible to cross-correlate the results with more precise fluorescence methods for studying binding kinetics, such as single-molecule tracking (SMT) microscopy. We used a previously developed refined reaction-diffusion model of the tau--MT interaction ([@B46]) to directly estimate the pseudo--first-order association rate (*k\**~on~ = *k*~on~\[MT\]~eq~, where \[MT\]~eq~ is the equilibrium concentration of tau-binding sites on MTs) and the dissociation rate (*k*~off~; also measurable by SMT) for all of the introduced constructs ([Figure 1D](#F1){ref-type="fig"}). Of note, the presence of the PRR did not influence *k\**~on~ but led to a remarkable change in *k*~off~, as indicated by a greater-than-sixfold increase upon deletion (2.20 ± 0.38 and 0.33 ± 0.05 s^−1^ for tauΔ369 and tauΔ401, respectively; *k*~off~ is expressed relative to the value for tau441wt, which was set to 1.0). This indicates that the PRR amplifies tau's binding to MTs by keeping it longer in the MT-bound state while having no influence on the association process of tau to MTs.

Isoform variation only moderately affects tau's interaction with MTs in neuronal processes
------------------------------------------------------------------------------------------

The data indicate that the presence of three or four RRs in the MBD has only a moderate effect on the tau--MT interaction in neuronal processes. This is exemplified by our observation that a deletion construct containing four RRs (tauΔ369) exhibits only a slightly lower *D*~eff~ than the construct with three RRs (tauΔ338), with no major change in either *k\**~on~ or *k*~off~ ([Figure 1D](#F1){ref-type="fig"}).

To address directly the question how isoform variation affects the interaction, we tested constructs containing or lacking the alternatively spliced exons in the N-terminus (N1, N2) and the MBD (RR2). For further comparison, we also prepared a construct lacking all alternatively spliced exons and the C-terminus including the PRR ([Figure 2A](#F2){ref-type="fig"}, left). All constructs were expressed in PC12 cells at the expected size with no obvious degradation ([Figure 2A](#F2){ref-type="fig"}, right). The FDAP curves for the different isoforms were very similar, and only the deletion constructs lacking the PRR (tau352Δ280) exhibited clearly increased decay ([Figure 2B](#F2){ref-type="fig"}, left, purple curve), similarly to the respective four-repeat isoforms (tauΔ369 vs. tau441wt; [Figure 1C](#F1){ref-type="fig"}). Determination of *D*~eff~ revealed that the fetal tau isoform (tau352wt) showed a small but significant increase compared with tau441wt. Deletion of the C-terminus containing the PRR had a much stronger influence compared with its full-length counterpart (tau352wt). The presence or absence of N1 and N2 did not influence the MT binding of tau. Calculating *k\**~on~ and *k*~off~ confirmed the similar behavior of the tau isoforms, whereas deletion of the PRR led to a significant decrease in *k*~off~ of the three-repeat constructs ([Figure 2C](#F2){ref-type="fig"}), in agreement with results for constructs containing four RRs ([Figure 1D](#F1){ref-type="fig"}).

![Isoform variation only moderately affects the tau--MT interaction in axon-like processes. (A) Schematic representation of the different CNS tau isoforms and a C-terminal deletion construct of the shortest tau isoform (left). The isoforms differ by the presence or absence of RR2 and adult-specific exons in the N-terminus (N1, N2). Right, immunoblot analysis of cellular lysates after transfection with the respective tau constructs. Detection used anti-GFP antibody. Molecular weight standards are indicated on the far right. (B) FDAP plots (left) and a diagram of the effective diffusion constants (right) for the different constructs. Note that the decay curves of tau383wt and tau352wt run together. Values are shown as mean ± SEM (error bars). Statistically significant differences of the isoforms relative to full-length tau (tau441wt; indicated by dotted line) are indicated by asterisks and between columns by dollar signs. (C) Bar plots showing *k*\*~on~ and *k*~off~ values of the respective constructs. The numbers are expressed relative to tau441wt. The reference value for full-length tau (tau441wt) and the meaning of the box plot are explained in the legend to [Figure 1](#F1){ref-type="fig"}. For the isoforms and the deletion construct, 10--45 cells were evaluated per set. *\*\*p* \< 0.01; ^\$\$\$^*p* \< 0.05.](3537fig2){#F2}

The PRR is highly conserved and constitutes a separate group in nearest-neighborhood cluster analysis
-----------------------------------------------------------------------------------------------------

We showed that the PRR has a dramatic effect on MT binding compared with other RRs, as indicated by a greater-than-sixfold increase in *k*~off~ upon deletion. This raises questions about similarities between the RRs and the PRR.

A generalized hidden Markov model (HMM) of the RR sequence was constructed as described in *Materials and Methods* and used to extract RR-similar sequences from 49 mammalian full-length sequences of MAP ([Figure 3A](#F3){ref-type="fig"}). Similarity relations were determined using a nearest-neighborhood cluster analysis of the extracted RR-similar amino acid sequences. Remarkably, the cluster analysis identified the PRR as a fifth group along with the common four RRs, with RR4 being most similar to the PRR ([Figure 3B](#F3){ref-type="fig"}).

![The PRR is highly conserved and constitutes a separate group in nearest-neighborhood cluster analysis. (A) HMM logo of the generalized Pfam (PF00418) seed alignment of the RRs. The position of the respective RR in human tau is shown at the bottom. (B) Unrooted tree of the RRs and the PRR of mammalian tau to visualize the relation between these regions. The colorized groups refer to the sequences included in further analysis. (C) Similarity of the mammalian PRR with the generalized Pfam HMM of the repeat regions determined by HMM-HMM comparison. The probability value as a measure of HMM similarity is plotted vs. number of amino acids consecutively added after the RR4. Red lines, position in the amino acid sequence at which the maximal probability is reached. (D) HMM logo of the 18--amino acid SM as determined in C. The position of the SM in human tau is shown beneath. Bottom, representative 3D structure of tau based on the RCG model. The MBD (yellow) and SM (orange) were mapped onto the structure. The end-to-end distance (distance between amino acids 1 and 441) is ∼25 nm. (E) Comparison of the SM with the MAPT HMMs of mammals, birds, reptiles, and ray-finned fish, as well as with generalized MAP2 and MAP4 HMMs.](3537fig3){#F3}

Our initial definition of the PRR implied that it is of similar length to other RRs. To determine the exact size of the most similar motif, the HMM-HMM comparison method proposed by [@B87]) was used. As a target HMM, the generalized HMM ([Figure 3A](#F3){ref-type="fig"}) was used, and the size of the PRR was determined using an iterative comparison approach (*Materials and Methods*). The similarity was highest at a length of 18 amino acids (aa; [Figure 3C](#F3){ref-type="fig"}). This was used to create a HMM of the similarity motif (SM) from mammalian tau sequences ([Figure 3D](#F3){ref-type="fig"}). The position of the SM in the human tau sequence is indicated below the HMM logo.

Tau belongs to a family of structural MAPs that share a conserved C-terminal domain containing the MT-binding domain. The family consists of the neuronal MAPs tau and MAP2 and the nonneuronal MAP4 ([@B20]; [@B92]). To determine phylogenetic conservation of the SM, we compared the SM's HMM from mammalian tau with those of tau from other classes (Aves, Reptilia, Actinopterygii) and generalized HMMs of MAP2 and MAP4. The results indicate that the SM is highly conserved across all classes in MAP tau (MAPT) and is also present in MAP2 and MAP4, suggesting that it serves as a general modulator of the MT interactions in all members of the MAPT/MAP2/MAP4 family. Of interest, the comparison also revealed a high similarity of the SM of tau to the RR4 of MAP2, supporting their close relation ([Figure 3E](#F3){ref-type="fig"}).

Pseudophosphorylation at the PHF-1 site does not affect MT interaction
----------------------------------------------------------------------

The data indicate that the presence of the PRR (aa 369--400) strongly enhances tau's interaction with MTs. It is therefore presumable that tau's MT interaction is regulated by phosphorylation in this region. Of interest, two disease-associated phosphorylation sites that are detected by the PHF-1 antibody occur in or close to the PRR. The PHF-1 antibody detects paired helical filaments of AD patients, recognizes NFTs and pretangles in various mouse models, and was used for immunization experiments aimed at decreasing tau pathology ([@B61]; [@B1]; [@B7]; [@B64]). To test the hypothesis that phosphorylation at the PHF-1 epitope affects the activity of the PRR to amplify tau--MT binding, we prepared tau mutants in which phosphorylation was either mimicked or blocked at the PHF-1 site (positions S396 and S404; [@B71]).

We did not detect a significant differ­ence between phosphomimicking (tau441~S396E/S404E~) and phosphoblocking tau mutants (tau441~S396A/S404A~) in FDAP experiments, which was evident from similar *D*~eff~ values for the respective constructs ([Figure 4A](#F4){ref-type="fig"}, left and middle). In addition, extraction of the on- and off-rates from the decay curves indicated a very similar behavior of the two constructs ([Figure 4A](#F4){ref-type="fig"}, right), suggesting that the amplifying effect of the PRR is robust against the phosphorylation state of the PHF-1 epitope. The results are consistent with previous in vitro data, for which phosphomimicking mutations in the PHF-1 site had been combined with mutations in other epitopes recognized by Alzheimer diagnostic antibodies (AT8, AT100); here only small effects on MT polymerization were observed ([@B48]).

![Effect of phosphomutations at the PHF-1 site and hereditary tauopathy mutations on the tau--MT interaction in neuronal processes. (A) Left, schematic representation of the tau phosphomutants (top) and FDAP plots (bottom) for the respective constructs. Middle, effective diffusion constants of the two phosphomutants. Right, bar plots with *k*\*~on~ and *k*~off~ values of the two constructs. (B) The hereditary tauopathy mutations, FDAP plots, a diagram of the effective diffusion constants, and bar plots with *k*\*~on~ and *k*~off~ values. The *D*~eff~ values are shown as mean ± SEM (error bars). For the bar plots, the numbers are expressed relative to tau441wt. Statistically significant differences relative to tau441wt are indicated at the top by asterisks. The meaning of the box plot is explained in the legend to [Figure 1](#F1){ref-type="fig"}. For the experiments, 8--23 cells (phosphomutants) and 15--30 cells (hereditary tauopathy mutations) were evaluated. \*\*\**p* \< 0.001.](3537fig4){#F4}

Hereditary tauopathy mutations located in the PRR do not affect apparent MT binding but increase the dynamicity of the interaction
----------------------------------------------------------------------------------------------------------------------------------

Two hereditary tauopathy mutations were previously reported in the PRR, K369I and G389R ([@B35]; [@B68]). In cell-free assays, both mutations reduced the ability of tau to promote MT assembly. To test whether these mutations affect tau's MT interaction in axon-like processes, we prepared tau expression constructs with the respective amino acid exchanges and tested them using our FDAP approach. Both mutants exhibited very similar FDAP decays and did not show a significant difference from the wild-type construct as judged from *D*~eff~ ([Figure 4B](#F4){ref-type="fig"}, left and middle). However, both constructs displayed much higher on- and off rates than with tau441wt, indicating that, although the overall binding is not changed, the mutations induce a higher dynamicity of the tau--MT interaction in axon-like processes.

Disease-like tau hyperphosphorylation in regions flanking the RRs and the PRR weaken tau--MT interaction by a strong decrease of *k*\*~on~
------------------------------------------------------------------------------------------------------------------------------------------

We demonstrated that phosphorylation at the disease-relevant PHF-1 site has no major influence on the tau--MT interaction in neurites. This poses the question of the extent to which other disease-relevant phosphorylation events, in particular an AD-like tau hyperphosphorylation, affect binding of tau to MTs.

Previously we prepared tau constructs in which 10 serine/threonine residues that are phosphorylated to a high extent in PHF-tau isolated from patients with AD were substituted with glutamate to create a pseudohyperphosphorylation of these residues. We showed that such pseudohyperphosphorylated tau constructs (PHP-tau) mimic key structural and functional aspects of hyperphosphorylated tau ([@B26], [@B27]; [@B62]). Cell culture experiments using PHP-tau provided evidence for a neurotoxic effect of soluble tau as a result of structural changes induced by cumulative, high-stoichiometric, and stable tau phosphorylation ([@B28]; [@B86]; [@B93]; [@B36]). In a transgenic *Caenorhabditis elegans* model, PHP-tau induced a developmental defect ([@B8]), and we observed altered tau phosphorylation at additional, nonmodified sites in transgenic mice ([@B44]).

In our FDAP experiments, tau441PHP exhibited a much more rapid fluorescence decay than tau441wt, indicating a weakened interaction with MTs ([Figure 5A](#F5){ref-type="fig"}). In fact, *D*~eff~ of the pseudohyperphosphorylated construct was approximately three times as high as for wild-type tau ([Figure 5B](#F5){ref-type="fig"}). Further analysis showed that the increased *D*~eff~ was mostly due to a decreased *k\**~on~ rate, whereas *k*~off~ increased only slightly without reaching significance ([Figure 5C](#F5){ref-type="fig"}). To cross-validate our FDAP measurements and determine the residence time of tau on MTs (1/*k*~off~), we used SMT analysis in which substoichiometrically labeled, Halo-tagged tau molecules were followed at high spatiotemporal resolution ([@B47]). PHP-tau rapidly moved within some tens of milliseconds between binding sites that were several hundred nanometers apart, suggesting rapid, undirected movement of tau molecules both longitudinally and transversally ([Figure 5D](#F5){ref-type="fig"}, left). This movement corresponded to the same kiss-and-hop interaction that we previously described for wild-type tau ([@B47]). Quantification revealed a mean residence time of 27 ms for PHP-tau ([Figure 5D](#F5){ref-type="fig"}, right), which was only slightly lower than the value for the wild-type construct (38 ms, as reported previously). Thus the SMT data support the finding that the increase of *D*~eff~ for tau441PHP was mainly due to a massive decrease in the *k\**~on~ rate. Although it is clear that PHP-tau is different from real pathological tau, the data are consistent with the view that disease-like tau modifications alter the way in which tau interacts with MTs, thereby facilitating a loss of tau from axonal MTs.

![Disease-like tau hyperphosphorylation in regions flanking the RRs and the PRR weaken the tau--MT interaction by a strong decrease of the *k*\*~on~-rate. (A) Schematic representation of wt and PHP tau (left) and FDAP plots (right) for the respective constructs. The 10 positions with serine/threonine-to-glutamate exchange are indicated by vertical lines. (B) Effective diffusion constants of wt and PHP tau. Values are as mean ± SEM (error bars). (C) Bar plots showing *k*\*~on~ and *k*~off~ values of the two constructs. The numbers are expressed relative to tau441wt. (D) Schematic representation of the Halo-tagged PHP-tau fusion construct (top right) and time series of individual Halo-PHP tau molecule moving in a process of a neuronally differentiated PC12 cell (left). Dashed lines indicate the border of the process. A trajectory generated from the complete time series (2.2 s = 440 frames) is shown at the far left, indicating an undirected, fast movement both longitudinally and transversally. The starting point is indicated by a circle and the end by a square. Scale bar, 0.5 μm. Bottom right, representative histogram of residence times of tau on MTs in PC12 cells. The single-exponential fit is indicated by a red line, and the time constant (residence time) is given on top. The residence time of wt tau was determined previously ([@B47]) and is indicated in gray. Mean ± SEM is shown (*n* = 3). The meaning of the box plot is explained in the legend to [Figure 1](#F1){ref-type="fig"}. *\*\*p* \< 0.01.](3537fig5){#F5}

Tau exhibits similar apparent MT binding in axons and dendrites that is more sensitive to increased protein phosphorylation in the axon
---------------------------------------------------------------------------------------------------------------------------------------

PC12 cells develop axon-like processes but do not show differentiation into axonal and somatodendritic compartments. To determine whether tau--MT interaction is compartment specific, we used primary cortical cultures from mice. To exclude potential interference with endogenous mouse tau, we prepared the cultures from tau-knockout mice and expressed PAGFP-tagged human tau (tau441wt) using a lentivirus. Axons and dendrites could be clearly distinguished using morphological criteria, with axons establishing a long process with uniform diameter and rectangular ramification, whereas dendrites showed a tapered morphology with branched cell processes ([Figure 6A](#F6){ref-type="fig"}, left, arrow vs. arrowhead). Photoactivation was performed in ∼6-μm-long, straight segments of the respective processes, and the fluorescence distribution was followed over 112 s ([Figure 6A](#F6){ref-type="fig"}, right).

![Tau exhibits similar apparent MT interaction in axons and dendrites that is sensitive to okadaic acid--induced increase in intracellular protein phosphorylation. (A) Example image of a primary cortical neuron lentivirally infected to express PAGFP-tau441wt (left). The neuron was photoactivated before imaging. The axon (arrow) and dendrites (arrowheads) are indicated. Right, representative time-lapse recording of the fluorescence distribution in the axon (top) or dendrite (bottom). (B) FDAP plots after photoactivation in the axon or dendrites of control cultures or cultures treated with okadaic acid. (C) Effective diffusion constants and (D) bar plots showing *k*\*~on~ and *k*~off~ values. The numbers in the bar plots are expressed relative to the respective control experiment (without okadaic acid). For the experiments, 39--54 processes were evaluated for each condition and compartment. The meaning of the box plot is explained in the legend to [Figure 1](#F1){ref-type="fig"}. \**p* \< 0.05, \*\**p* \< 0.01.](3537fig6){#F6}

The FDAP decays for both axonal and dendritic tau were similar, which resulted in similar values for *D*~eff~ ([Figure 6, B and C](#F6){ref-type="fig"}). The apparent association and dissociation rates as extracted in our FDAP analysis are directly proportional to the MT density ([@B46]). Taking into account published data on the distance between MTs in axons and dendrites from rat brain (20--30 vs. 60--70 μm, respectively; [@B15]), we can estimate real kinetic constants of 83.5 (axon) and 460.9 s^−1^ (dendrite) for the pseudo--association rate and 3.3 (axon) and 20.8 s^−1^ (dendrite) for the dissociation rate. The values clearly differ between these compartments and may be due to the generally higher phosphorylation state of dendritic tau ([@B73]; [@B63]; [@B62]).

To determine the potential effect of increased phosphorylation, we treated the cultured neurons with the phosphatase inhibitor okadaic acid (OA) before imaging. The OA treatment increased the mobility of PAGFP-tau in both compartments, indicating a weakened MT interaction ([Figure 6B](#F6){ref-type="fig"}). Extraction of the on- and off-rates from the FDAP curves showed that the effect of phosphorylation was much more pronounced in the axonal compartment, in which OA induced a twofold-to-threefold increase in on- and off-rates (2.39 and 2.69 s^−1^, respectively), whereas the change was \<1.5 in dendrites (1.09 and 1.45 s^−1^, respectively; [Figure 6D](#F6){ref-type="fig"}). Thus the data suggest that tau--MT interaction in the axon is more sensitive to increased phosphorylation than in the dendrite. Note, however, that OA is likely to change the phosphorylation state of many proteins in addition to tau and that the effect of OA on tau depends on the basal phosphorylation of many individual sites.

DISCUSSION
==========

The neuronal axon represents a unique cellular compartment, as it contains an array of densely packed, parallel MTs specialized for structural stabilization and efficient transport over long distances. Under physiological conditions, the axon is the natural environment for the majority of the MT-associated protein tau. We previously addressed the paradox that tau, although mostly bound to MTs at every time point, does not interfere with MT-dependent transport. The explanation is the kiss-and-hop mechanism, according to which tau rapidly interconverts between free and MT-bound states with a dwell time of ∼40 ms on a single MT ([@B46]; [@B47]). Here we addressed how the binding of tau is regulated and how disease-like modifications affect the tau--MT interaction in axon-like processes.

Our refined FDAP approach allows us to determine several functional parameters of the tau--MT interaction in living cells, providing a more precise understanding of tau's behavior in neuronal compartments. Our major findings are as follows: 1) tau isoform variation has only a minor effect on its MT interaction in axon-like processes; 2) the presence of a conserved PRR at tau's extreme C-terminus greatly enhances MT binding by decreasing the dissociation rate; 3) disease-associated tau mutations in the PRR do not influence apparent MT binding but increase the dynamicity of the tau--MT interaction; 4) simulation of a disease-like tau hyperphosphorylation dramatically diminishes the association rate of tau to MTs but does not change the kiss-and-hop nature of this interaction; and 5) the apparent tau-MT binding is similar in axons and dendrites but is more sensitive to increased phosphorylation in the axon.

In the CNS, tau is present in six isoforms, which differ by the presence or absence of three alternatively spliced exons. With respect to the MT association, exon 10, which codes for an additional repeat region (RR2), has been in the focus of intense research. Interest has also been provoked by the finding that some tauopathies are associated with a misbalance in isoform expression toward four-repeat isoforms by inclusion of exon 10 ([@B88]). Previously, using a fixation protocol after microinjection of recombinant tau constructs, *K*~D~ values of 1.1 and 2.5 μM were estimated for 441wt and 352wt tau, respectively, in the cytosol of cultured cells ([@B78]), suggesting some difference in binding. The difference in *K*~D~ corresponds to in vitro data, for which an approximately threefold increase in binding activity of 4R- versus 3R-tau has been reported ([@B11]; [@B39]). Our FDAP data from axon-like processes indicate an increase of only ∼1% in the amount of MT-bound tau for the 4R- compared with the 3R-isoform. Therefore, in contrast to the conditions in vitro and in the cell body, isoform variation has only a minor effect on MT binding in the presence of the densely packed MT arrays that prevail in the axon. Thus isoform variation is unlikely to affect the axonal localization of tau but might modulate other properties of the axonal MT array, such as by determining the spacing between MTs or mitochondrial localization ([@B10]; [@B90]; [@B16]).

As discussed earlier, we observed considerable differences between our results on the interaction of tau with MTs in living cells and previous in vitro binding studies. Among the reasons for disagreement could be that in vitro binding studies mostly used Taxol-stabilized MTs. It is known, however, that Taxol induces structural changes in the MT lattice ([@B69]; [@B101]), and we and others previously showed that treatment of cells with Taxol results in a detachment of tau from MTs, which decreases the fraction of MT-associated tau by almost 20% ([@B84]; [@B96]). In fact, it was also reported that the apparent tau--MT affinity as determined in vitro depends on the methods and protein concentrations used and that Taxol-stabilized MTs can even promote tau filament formation ([@B24]). Of interest, tau's ability to promote MT assembly under Taxol-free conditions appears to better reflect its interaction in cells, as evidenced by a similar critical concentration of tau-dependent MT assembly for the 3R and 4R isoforms ([@B9]; [@B72]).

In contrast to the effect of exon 10, truncation of a pseudorepeat region at tau's C-terminus strongly diminished the tau--MT interaction by a more-than-sixfold increase of the dissociation rate. We and others previously showed that regions flanking tau's MT-binding domain modulate MT-related activities of tau in vitro and in nonneuronal cells ([@B9]; [@B39]; [@B78]; [@B37]). However, the strong effect of the PRR is also surprising with respect to previous observations in vitro in which the C-terminal tail increased the MT association of 3R-tau but had only a negligible effect for 4R-tau ([@B37]). In contrast, our data show that deletion of the C-terminal tail strongly decreases tau's MT binding for both the 3R- and the 4R-isoforms ([Figures 1C](#F1){ref-type="fig"} and [2B](#F2){ref-type="fig"}), suggesting that this region amplifies tau's interaction with the axonal MT array independent of the isoform and could be important for retaining tau in the axonal compartment. Our data are consistent with results from recent in vitro experiments in which regions involved in tau's binding to MTs have been identified by nuclear magnetic resonance ([@B51], [@B52]). Here signal broadening indicative for MT interaction was also observed for tau residues 375--398, which are located in the PRR, and cross-links of Lys-383 to tubulin were reported.

Conditions that affect the integrity of the PRR could have a critical role in triggering the redistribution of tau during tauopathies. In fact, C-terminal truncation of tau at the caspase-3 cleavage site located at Asp-421 appears to be an early event in disease ([@B31]) and might link amyloid β and tau pathology ([@B33]). Furthermore, the tau fragment within the core of PHFs has been identified to be C-terminally truncated at Glu-391 ([@B99]), a position that is located within the PRR. In addition, C-terminal cleavage might also facilitate the release of tau from neurons, since secreted tau species have been described as being C-terminally truncated ([@B53]). Thus disease-related C-terminal truncation of tau could initiate a multitude of potentially disease-relevant events, including diminished axonal MT binding and neuronal release.

Bioinformatic analysis revealed the PRR as a fifth homology group in addition to the common four RRs and identified an 18--amino acid long motif (SM) with high similarity across different tau species. The SM was also highly homologous to the corresponding region in other members of the MAPT/MAP2/MAP4 family. It was previously assumed that the nonneuronal MAP4 is unique and contains no sequence similarity in the respective region ([@B13]). However, we identified a similar motif in MAP4, which suggests that this modulating region is present in the nonneuronal MAP4 as well. Thus it appears that the SM developed early during evolution before the diversion of the neuronal MAPs at the dawn of the vertebrates ([@B20]; [@B92]).

Simulation of a disease-like hyperphosphorylation using a model of pseudohyperphosphorylated tau did not affect the kiss-and-hop characteristics of the tau--MT interaction but caused a strong decrease of MT binding, which was attributed mainly to a decrease in the association rate. In contrast, hereditary tau mutations at the PRR did not affect tau's overall MT binding but increased the dynamicity of the interaction with MTs in axon-like processes. In some cases, the G389R mutation was associated with an extreme early onset of dementia that developed in juvenile patients ([@B5]; [@B14]). This could indicate that changes in the dynamicity of tau's axonal MT interaction rather than effects on overall MT binding have a decisive role in the development of tauopathies.

We showed that, despite different intermicrotubule distances, overall apparent tau--MT binding is similar in axons and dendrites. This implies that the real kinetic constants of tau differ between these compartments, which may be due to the higher phosphorylation state of dendritic tau ([@B73]; [@B63]; [@B62]). Note, however, that spacing between MTs may become much larger during aging and neurodegenerative conditions since significant MT reduction in both density and length was observed in human pyramidal neurons during AD and aging ([@B12]). In addition, MT dynamicity appears to increase with age and in pathological conditions ([@B76], [@B77]). The change in MT spacing will affect the apparent association and dissociation rates of tau and could affect the influence of mutations or phosphorylation on the interaction with the axonal MT array, thereby contributing to mislocalization of tau under pathological conditions.

MATERIALS AND METHODS
=====================

Materials and antibodies
------------------------

Chemicals were obtained from Sigma-Aldrich (Deisenhofen, Germany), and cell culture media, supplements, culture flasks, plates, and dishes were obtained from Sigma-Aldrich and ThermoFisher Scientific (Schwerte, Germany), unless stated otherwise. The following antibodies were used: anti-GFP (chicken; Aves, Tigard, OR) and peroxidase-conjugated donkey anti-chicken antibodies (Jackson Im­munoResearch Laboratories, West Grove, PA).

Construction of expression vectors, transfections, and lentiviral infections
----------------------------------------------------------------------------

Eukaryotic expression plasmids for tau deletion constructs, tau isoforms, and tau mutants (S396A/S404A, S396E/S404E, G389R, K369I) with amino-terminally fused PAGFP tag were constructed in pRc/cytomegalovirus (CMV)--based expression vectors (Life Technologies, Carlsbad, CA) containing a CMV promoter and kanamycin and neomycin resistance genes. Constructs coding for tau441PHP and the respective wt control were constructed in pSems-based expression vectors ([@B98]). Deletion constructs were constructed by addition of stop codons (TAA for tauΔ276, Δ307, Δ338, Δ369, and tau352Δ280 and TAG for tauΔ401) at the indicated position. The pCMV-3 × PAGFP plasmid was described previously ([@B96]). Lentiviral vectors for tau441wt with amino-terminally fused PAGFP tag were constructed in L22FCK(1.3)GW (provided by P. Osten, Northwestern University, Chicago, IL), which contains the neuron-specific promoter α-CaMKII ([@B23]). Sequences that were introduced by PCR were verified by DNA sequencing (Seqlab-Microsynth, Göttingen, Germany).

Transfections of PC12 cells were performed with Lipofectamine 2000 (Invitrogen) essentially as described previously ([@B28]). For production of lentivirus, human embryonic kidney cells 293FT (Life Technologies) were transfected with the expression vector and two helper plasmids, and viral particles from the supernatant were concentrated by ultracentrifugation as described previously ([@B4]).

Cell culture and live-cell labeling
-----------------------------------

PC12 cells were cultured in serum-DMEM as described previously ([@B28]). Undifferentiated cells were plated on 35-mm poly-[l]{.smallcaps}-lysine-- and collagen-coated glass-bottom culture dishes (MatTek, Ashland, MA) at 10^3^--10^4^ cells/cm^2^ and cultured in DMEM with 1% (vol/vol) serum without phenol red. For total internal reflection fluorescence (TIRF) imaging, cells were plated on glass coverslips (24 mm, No. 1; VWR, Radnor, PA) coated with a poly-[l]{.smallcaps}-lysine-graft-(polyethylene glycol) copolymer functionalized with RGD as described previously ([@B94]). For neuronal differentiation, cells were treated with 100 ng/ml 7S mouse nerve growth factor (Alomone Laboratories, Munich, Germany) for 4--6 d, and the medium was changed after 2--3 d. Primary cortical cultures were prepared from cerebral cortices of mouse embryos (days 14--16 of gestation) and cultured as described previously ([@B4]). The cultures were obtained from *TAU*^−*/*−^ mice ([@B19]) on a C57BL/6 background. Cells were plated at 2.5 × 10^4^ cells/cm^2^ on polylysine- and laminin-coated coverslips. For imaging, the medium was exchanged against NEUMO with supplements for neuronal cells as described in the user guidelines of the manufacturer (Cell Guidance Systems, Cambridge, United Kingdom).

Labeling of PC12 cells for TIRF imaging was performed by incubation with serum-DMEM containing 1--5 nM tetramethylrhodamine--HaloTag ligand for 15 min at 37°C. This corresponded to a labeling efficiency of \<0.02% of the exogenous Halo-tau. Subsequently, cells were washed with serum-DMEM without phenol red and then left to recover for 30 min in the incubator, followed by an additional medium exchange. All animals were maintained and killed according to National Institutes of Health guidelines and German animal care regulations.

Photoactivation and live imaging
--------------------------------

Live imaging was performed using a laser scanning microscope (Eclipse TE2000-U inverted; Nikon, Tokyo, Japan) equipped with argon (488-nm) and blue diode (405-nm) lasers. PAGFP-tau--expressing cells were visualized with a Fluor 60× (numerical aperture \[NA\] 1.4) ultraviolet-corrected objective lens. The microscope was enclosed in an incubation chamber maintained at 37°C and 5% CO~2~ (Solent Scientific, Fareham, United Kingdom). Automated image acquisition after photoactivation was essentially performed as described previously ([@B46]). Photoactivation of a neurite's segment of ∼6 μm in length was performed with a blue diode. A set of consecutive images (time stack) was obtained at a frequency of 1 frame/s, and 112 frames were collected per experiment. All stacks were collected at a resolution of 256 × 256 pixels.

Single-molecule microscopy, localization, and tracking
------------------------------------------------------

For performing single-molecule experiments, TIRF microscopy was performed using an Olympus excellence cell TIRF microscope equipped with 561-nm (200-mW) laser (Olympus, Tokyo, Japan) and a back-illuminated electron-multiplied charge-coupled device camera (C9100-13; Hamamatsu, Hamamatsu City, Japan). Fast single-molecule tracking used a digital complementary metal--oxide--semiconductor camera (ORCA-Flash4.0 V2 C11440-22CU; Hamamatsu). A 150× magnification objective with NA 1.45 (UAPON 150×/1.45; Olympus) was used for TIR illumination. The emitted light from the sample was filtered using a quad-band bandpass filter (FF01 446/523/600/677; Semrock, Rochester, NY). The microscope was enclosed in an incubation chamber maintained at 37°C and 5% CO~2~ (Olympus-PeCon). Localization and trajectory reconstruction were carried out as previously described ([@B47]). The theoretical localization precision of Halo-tau was 16.7 ± 0.2 nm. For further analysis, a mask was placed over the cell processes, and trajectories outside of this mask were removed.

Dwell-time determination
------------------------

The dwell time of tau in the MT-bound state was determined by counting how many consecutive frames a single localized signal stayed within a radius of 50 nm. The respective frequency histograms were fitted by a single exponential to obtain the dwell time.

FDAP data analysis
------------------

Effective diffusion constants were determined by fitting the data from photoactivation experiments by a model FDAP function described in [@B96]). To estimate directly the pseudo--first-order association rate (*k*\*~on~ = *k*~on~\[MT\]~eq~, where \[MT\]~eq~ is the equilibrium concentration of tau binding sites on MTs) and the dissociation rate (*k*~off~) of tau to/from MTs, we used a reaction-diffusion model of the tau--MT kinetics as described in [@B46]). Analysis of individual FDAP curves was performed with a custom C-based tool called *cFDAP* ([www.github.com/moozzz/cFDAP](http://www.github.com/moozzz/cFDAP)). The tool uses the Levenberg--Marquardt algorithm to solve the weighted and unweighted problems of multidimensional nonlinear least-square fitting ([@B65]) implemented in the GNU Scientific Library ([@B32]). Generally, the problem reads as follows: where *f*(*t*) represents the average of several FDAP curves sampled on a time set *t~i~*, FDAP(*t*, ***β***) is a model FDAP function also sampled on *t~i~*, ***β*** is a vector of parameters to be varied during the fitting procedure (in our case, ***β*** *=* (*k\**~on~, *k*~off~)), ω*~i~* = 1/σ*~i~*^2^, and σ*~i~* is the error for the *i*th time point. Because all FDAP curves were analyzed individually, the unweighted scheme was chosen, in which ω*~i~* ≡ 1. The Levenberg--Marquardt algorithm iteratively minimizes the function in (1). To start the minimization, the user has to provide an initial guess for the parameter vector. In each iteration step, the parameter vector ***β*** is then replaced by ***β*** + *Δ**β***, and the FDAP model function is approximated by a linearization: where *J~i~ = ∂*FDAP(*t~i~*, ***β***)/*∂**β*** is the gradient of FDAP(*t*, ***β***) with respect to ***β***. At the minimum of the sum of squared residuals (1), the gradient (2) is expected to be zero. The theoretical basis underlying the model FDAP functions used in the present work was given previously ([@B46]). The fitting procedure was used to extract *k*\*~on~ and *k*~off~ from every single FDAP curve for every tau construct. The *χ*^2^ value was used as an indicator of goodness of fit. All of the three values (*k*\*~on~, *k*~off~, and *χ*^2^) are independent and, in fact, random values with certain distributions. Hence, before computing averages or comparing the binding parameters for different tau constructs with each other, we needed to ensure that the obtained *k*\*~on~, *k*~off~, and *χ^2^* samples contained no statistical outliers (SOs). We used the following protocol to exclude SOs. First, we verified whether all of the three parameters were normally distributed. The D'Agostino--Pearson test for normality showed that the majority of the samples are not normally distributed (*p* \< 0.9). However, upon a logarithmic transformation (ln(*k*\*~on~), ln(*k*~off~), and ln*(χ*^2^)), all of the tested samples demonstrated high *p* values (*p* \> 0.9) in the D'Agostino--Pearson test. We thus concluded that *k*\*~on~, *k*~off~, and *χ^2^* are log-normally distributed values. For all subsequent analyses, the samples were logarithmically transformed, and only the transformed samples were further processed. We then verified whether there was a linear statistical correlation between ln(*k*\*~on~) and ln(χ^2^) and between ln(*k*~off~) and ln(*χ^2^*). For the majority of tau constructs, the mentioned sample pairs were highly uncorrelated (*R*^2^ \< 0.1), and only a minority showed a weak correlation (*R*^2^ ∼ 0.1--0.2). This allowed us to conclude that both ln(*k*\*~on~) and ln(*k*~off~) samples are linearly statistically independent of ln(*χ*^2^) and perform the subsequent SO detection independently for ln(*k*\*~on~), ln(*k*~off~), and ln(*χ*^2^). Finally, we eliminated SOs in the ln(*χ*^2^) samples by using Iglewicz and Hoaglin's robust test, as those SOs represented bad fits and had to be removed first. Then we repeated this procedure for ln(*k*\*~on~) and ln(*k*~off~).

Bioinformatic analysis
----------------------

### Definition of the PRR.

We followed the definition by [@B13]), who reported the presence of an extra 14--amino acid spacer segment directly after the fourth repeat region (RR4) of tau followed by a truncated repeat. The PRR was defined as a motif starting directly after RR4 and extending to the same length as an RR (31 amino acids).

### Analysis of the relationship between the RRs and the PRR.

The relation between the different RRs and the PRR was determined by a cluster analysis of the amino acid sequences of the respective regions. The sequences of the RRs and the PRR were automatically identified by HMM-based search ([@B25]; [@B29]) of the generalized Pfam ([@B30]) from tau and MAP tubulin-binding repeats (PF00418, tubulin-binding, tau, and MAP protein, tubulin-binding repeat) versus a previously manually cured collection of 49 mammalian full-length sequences (776 amino acids in length). The generalized Pfam HMM was created with the *hmmbuild* tool of the HMMER 3.1b2 package and was based on a seed alignment (114 sequences) of the PF00418 entry. The resulting hits were extracted by a self-written python script with the help of the *biopython* library (Python Software Foundation, [www.python.org/psf/;](http://www.python.org/psf/;) [@B17]). The resulting hits were collected in a single file, and a cluster analysis was performed in the R software suite with the help of the *phangorn* package ([@B102]; [@B85]). The distance matrix for the cluster analysis was calculated using the Johns--Tyler--Thornton model of amino acid evolution ([@B50]). The clusters were generated by a neighbor-joining algorithm ([@B83]) implemented in the *phangorn* package. Supporting bootstrap values for the splits were generated by 10^4^ replications, and the majority-rule consensus tree was created by the *sumtree.py* software ([@B91]). The tree was converted into an unrooted tree to visualize the grouping using the *dendroscope* software ([@B45]).

### Definition of the SM and HMM-HMM comparisons.

To determine the part of the PRR that shows the largest similarity to the RRs, we used a HMM-HMM comparison method as proposed by [@B87]). The Pfam generalized HMM was used as a query HMM. To determine the size of the SM, an iterative comparison approach was chosen. The number of columns of the target alignment (sequence following the fourth repeat) was iteratively increased one amino acid per step, and the corresponding HMM was built and compared with the query Pfam HMM. The maximum probability was reached when the SM was 18 amino acids long. This value (18 amino acids) was used to set the border of the SM. The alignment was then used to build a HMM, which was visualized as a HMM logo by the *skyalign* package ([@B25]; [@B97]). The previously derived PRR-HMM was compared with the HMM of other classes (Aves, 15 sequences; Reptilia, 12 sequences; Actinopterygii, 16 sequences), as well as with general HMMs of MAP2 (87 sequences from all classes) and MAP4 (110 sequences from all classes; [@B87]; [@B92]). All of the mentioned HMMs (MAPT/2/4) were based on manually cured sequence reconstructions.

### Visualization of the three-dimensional structure of tau.

A representative three-dimensional (3D) structure of tau (441-aa isoform) was generated by Random Coil Generator (RCG) software ([@B49]). The random coil model is frequently used to generate conformational ensembles of intrinsically disordered proteins. In the RCG model, intramolecular interactions are neglected, and only backbone conformational frequencies from the coil library of the Protein Data Bank ([www.rcsb.org/](http://www.rcsb.org/)) are used to generate the ensemble. The domain organization was mapped onto the 3D structure. Visualization and structure rendering was performed using the Visual Molecular Dynamics package as surface representation ([@B43]).

Other methods
-------------

SDS--PAGE and immunoblot analysis by enhanced chemiluminescence were performed as described previously ([@B59]). Cellular lysates were prepared in radioimmunoprecipitation assay buffer (50 mM Tris/HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.5% deoxycholate, and 0.1% SDS) containing protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 10 μg/ml each leupeptin and pepstatin, and 1 mM ethylene glycol tetraacetic acid), and 20 μg of total protein were loaded per lane. Protein concentration was determined using a bicinchoninic acid protein assay kit (Thermo Fisher Scientific, Waltham, MA). Statistical analysis was performed using two-tailed, unpaired Student's *t* test. The α-levels were defined as follows: *\*p* \< 0.05, \*\**p* \< 0.01, and *\*\*\*p* \< 0.001.

This article was published online ahead of print in MBoC in Press (<http://www.molbiolcell.org/cgi/doi/10.1091/mbc.E16-06-0402>) on August 31, 2016.
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